NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a dea

GAD affects approximately 26 million U.S. adults, and when left untreated, can cause chronic, pervas

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in De

Data highlight the challenges of achieving response and sustained remission in newly diagnosed and e

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”),

Stifel analyst Paul Matteis maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises t

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Bu

Health care stocks flashing warning to momentum investors. RSI indicator shows overbought for DFTX,

Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial opera

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”),

After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs

Dow Jones index gained 200 points; Acuity Inc (NYSE: AYI) reported better-than-expected financial re

Jones Trading analyst Justin Walsh maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and r

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clini

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”),

DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers r

Definium Therapeutics (DFTX) stock hits $38.24 after positive clinical data, but an 84.57 RSI signal

Top Wall Street analysts changed their outlook on top names. Complete view of changes, incl. upgrade

Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform a

Needham analyst Ami Fadia maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the

Definium Therapeutics, Inc. (NASDAQ:DFTX) (the "Company" or "Definium"), a late-stag

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”),

Leerink Partners analyst Marc Goodman maintains Definium Therapeutics (NASDAQ:DFTX) with a Outper

Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and

Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical c

Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 79.6% to $0.63 during Monday's regul

Definium Therapeutics, Inc. (DFTX) Shareholder/Analyst Call Transcript

U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Thera

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 300 poi

Definium Therapeutics Inc. (NASDAQ:DFTX) shares are surging Monday after the company announced posit

Definium shares are surging Monday after the company announced positive topline results from its Pha

Gainers Tenon Medical (NASDAQ:TNON) shares increased by 115.8% to $0.76 during Monday's pre-mar

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical bio

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage c

Definium Therapeutics NASDAQ: DFTX Chief Financial Officer Brandi Roberts said the company is prepar

Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stag

Health officials explored restricting specific antidepressants among SSRI drugs-sources

Piper Sandler analyst David Amsellem maintains Definium Therapeutics (NASDAQ:DFTX) with a Overwei

Definium Therapeutics (NASDAQ:DFTX) reported quarterly losses of $(0.71) per share which missed the

https://www.hhs.gov/press-room/fda-accelerates-action-treatments-serious-mental-illness-following-ex

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patien

Definium Therapeutics stock rises after hours amid psychedelic sector rally following Trump's re

Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump